GE HealthCare Appoints Rodolphe Katra as Chief AI Officer

GE HealthCare has appointed Rodolphe Katra as its new Global Chief AI Officer, as the medical technology company looks to expand its use of AI across devices, software and healthcare data.

Rodolphe joins from Medtronic, where he served as Chief AI Officer for the past three years.

Following in the footsteps of GE HealthCare’s former AI chief Parminder Bhatia, who left the company in July 2026, Rodolphe will report to Global Chief Science and Technology Officer Taha Kass-Hout.

The appointment comes as GE HealthCare seeks to build on a sizeable portfolio of AI-enabled medical devices. According to CEO Peter Arduini, the company has 134 AI-enabled medical devices authorised for medical use by the US Food and Drug Administration (FDA) – more than any other medtech company.

Welcoming Rodolphe to the role on LinkedIn, Peter writes: “Working closely with our segment teams, Rodolphe will help us take our AI strategy to the next level – connecting devices, software and data to deliver better insights, more longitudinal understanding and more precise care.”

“At GE HealthCare, our goal is simple: build AI-enabled solutions that are making a difference for patients, clinicians and health systems. That’s how we deliver growth and long-term value,” he adds.

From Medtronic to GE HealthCare

Rodolphe brings 25 years of experience across the industry and, most recently, more than a decade at Medtronic, where he held several leadership positions spanning research and development and technology.

As Medtronic’s Chief AI Officer, he led the creation of the company’s first enterprise-wide AI Centre of Excellence, alongside developing AI governance frameworks and an enterprise AI strategy.

He also oversaw the scaling of AI adoption across Medtronic’s 15 business units, operating across more than 160 countries, while leading initiatives spanning enterprise AI, digital health and advanced analytics.

Within Medtronic’s Cardiac Rhythm business, which has more than US$6bn in revenue, Rodolphe also supported the use of AI and digital technologies to modernise operations, expand connected care and accelerate clinical innovation.

Commenting on his appointment at GE HealthCare on LinkedIn, Rodolphe writes: “GE HealthCare is a storied company with a remarkable legacy of innovation, including leading the industry in FDA AI authorisations.

“It’s a privilege to join at such a pivotal moment for AI in healthcare, and to help take this work to the next level – connecting devices, software, and data to deliver better insights and more precise care for clinicians and patients.”

Building on a long-standing AI strategy

GE HealthCare has ranked first for the number of FDA-authorised AI-enabled medical devices for five consecutive years, according to the company.

Its AI strategy spans medical imaging, clinical workflows and operational applications, with the company increasingly exploring how AI can connect data and systems across the patient journey.

That strategy was highlighted on 23 September 2026, when GE HealthCare announced a partnership with Boston, Massachusetts-based Mass General Brigham to explore the use of generative AI in radiation therapy.

The collaboration will focus on helping radiation oncology teams bring together and interpret information needed to plan and deliver cancer treatment, which can currently be distributed across multiple systems.

The partners plan to develop a generative AI tool that could be integrated with GE HealthCare’s Intelligent Radiation Therapy (iRT) software. The platform is designed to support radiation therapy workflows by connecting tools, coordinating activities and reducing manual handoffs between different stages of care.

The aim is to give clinical teams faster access to relevant information while helping patients move more efficiently from diagnosis towards treatment.

Illustrating the velocity of GE HealthCare's AI launches, the company also launched CareIntellect for Operations on 15 September 2026, an AI-enabled software-as-a-service application designed to help healthcare organisations anticipate operational pressures.

The platform can forecast potential capacity constraints up to 72 hours in advance by analysing patient and operational data, including bed availability, staffing levels and other hospital activity.

Rodolphe’s appointment adds a new layer of enterprise AI leadership as the company seeks to connect these technologies more closely across its portfolio.

GE HealthCare - key partners

NVIDIA

CEO: Jensen Huang | HQ: Santa Clara, California, US

NVIDIA and GE HealthCare have a long-standing technology partnership focused on applying AI to medical imaging. Their collaboration has expanded into autonomous imaging, including X-ray and ultrasound, with NVIDIA’s computing infrastructure supporting GE HealthCare’s development of AI-enabled technologies. The relationship is particularly relevant to GE HealthCare’s broader strategy of integrating AI into medical devices and clinical workflows.

Mass General Brigham

CEO: Anne Klibanski | HQ: Boston, Massachusetts, US

Mass General Brigham and GE HealthCare have collaborated on healthcare AI and clinical research for several years. Their latest work explores generative AI for radiation oncology, with the aim of bringing together structured clinical data and unstructured information from multiple systems. The partnership builds on technology developed at Massachusetts General Hospital that became part of GE HealthCare’s Intelligent Radiation Therapy solution.

Mayo Clinic

CEO: Gianrico Farrugia | HQ: Rochester, Minnesota, US

GE HealthCare and Mayo Clinic have developed a strategic research relationship spanning medical imaging, AI, theranostics and radiation therapy. Their GEMINI-RT initiative focuses on integrating imaging, AI and patient monitoring to advance personalised radiation treatment. A further 2026 collaboration is exploring data-informed approaches to personalise radioligand therapy for patients with advanced prostate cancer.